NFE2L2 and Friedreich ataxia: Therefore, our findings, besides confirming a central role for NRF2 in the pathogenesis of FRDA, can contribute to developing targeted therapies, through the use of drugs aimed at preventing inflammation (i.e., SFN, NAC), lipid peroxidation (DMF, OMAV, EPI-743), or redox imbalance (SFN), based on the patient’s clinical conditions and their therapeutic needs.